Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906906 | 1.00 | GLP1R (0.49) | GLP1RCA1CA2SIRT6SIRT1 | |
| SCHEMBL23995632 | 0.99 | GLP1R (0.50) | GLP1RCA1CA2SIRT6SIRT1 | |
| SCHEMBL18911933 | 0.88 | GLP1R (0.45) | GLP1RCA1CA2CTSSCTSK | |
| SCHEMBL18912601 | 0.88 | GLP1R (0.41) | GLP1RCA1CA2SIRT6SIRT1 | |
| SCHEMBL13699550 | 0.84 | GLP1R (0.54) | GLP1RCA1CA2CTSSCTSK | |
| SCHEMBL13699549 | 0.84 | GLP1R (0.56) | GLP1RCA1CA2CTSSCTSK | |
| SCHEMBL3485167 | 0.83 | GLP1R (0.51) | GLP1RCA1CA2ADORA1 | |
| SCHEMBL3486505 | 0.83 | GLP1R (0.51) | GLP1RCA1CA2ADORA1 | |
| SCHEMBL4517738 | 0.83 | GLP1R (0.54) | GLP1RSIRT6SIRT1TLR2 | |
| SCHEMBL3484885 | 0.83 | GLP1R (0.54) | GLP1RSIRT6SIRT1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-11173214-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-16 | — | — | US | disclosed |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20200297865-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2020-09-24 | — | — | US | disclosed |
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2019-05-23 | — | — | US | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | GLP1R 1694/4885CA1 569/4885CA2 2471/4885 |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | DAO, LPO, TYRO3 | GLP1R 129/4885CA1 106/4885CA2 807/4885 |
| US-11173214-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | PA2G4, FCGRT, CLTB | GLP1R 1694/4885CA1 569/4885CA2 2471/4885 |
| US-20200297865-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LPO, NOXO1, DAO | GLP1R 1774/4885CA1 222/4885CA2 1164/4885 |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | GLP1R 1694/4885CA1 569/4885CA2 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.